KYPROLIS is engineered for selective inhibition1
• Single-agent KYPROLIS phase 2 study results2,*
- Overall response rate (ORR) of 22.9% in PX-171-003 study (95% CI: 18.0, 28.5)
- Median duration of response of 7.8 months (95% CI: 5.6, 9.2)
• Most patients across all phase 2 studies (85%) did not need to discontinue therapy due to an adverse event
- Adverse reactions leading to discontinuation included congestive heart failure (2%), cardiac arrest,
dyspnea, increased blood creatinine, and acute renal failure (1% each)
ADVERSE REACTIONS
The safety of KYPROLIS was evaluated in clinical trials of 526 patients with relapsed and/or refractory
multiple myeloma.
• Serious adverse reactions were reported in 45% of patients. The most common were pneumonia (10%),
acute renal failure (4%), pyrexia (3%), and congestive heart failure (3%)
• The most common adverse reactions (incidence ≥ 30%) were fatigue (56%), anemia (47%), nausea (45%),
thrombocytopenia (36%), dyspnea (35%), diarrhea (33%), and pyrexia (30%)
*Study PX-171-003 was a single-arm, multicenter clinical trial of KYPROLIS in 266 patients with relapsed multiple myeloma and whose disease had
a ≤ 25% response to the most recent therapy or had disease progression during or within 60 days of the most recent therapy. At the time of
study entry, patients had received a median of 5 prior lines of t